| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| GILDGilead Sciences, Inc. | 185.59B | 148.95 | 391.97 | 6.04% | 28.9% | 37.62% | 5.55% | 1.39 |
| ABBVAbbVie Inc. | 410.09B | 232.03 | 97.08 | 3.71% | 4% | 62.18% | 4.35% | 20.17 |
| AMGNAmgen Inc. | 209.22B | 388.16 | 27.28 | 9.95% | 20.99% | 89.06% | 3.87% | 6.31 |
| BIIBBiogen Inc. | 28.15B | 191.82 | 21.72 | 1.39% | 13.18% | 7.08% | 7.28% | 0.38 |
| NVONovo Nordisk A/S | 126.28B | 37.45 | 10.30 | 2.34% | 33.14% | 50.76% | 7.09% | 0.67 |
| SCLXScilex Holding Company | 1.5B | 8.21 | -0.42 | 21.07% | -9.31% | 1.29% |
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Sales/Revenue | 23.56M | 31.32M | 38.03M | 46.74M | 56.59M |
| Revenue Growth % | - | 32.92% | 21.45% | 22.9% | 21.07% |
| Cost of Goods Sold | 2.15M | 3.63M | 10.8M | 15.68M | 16.69M |
| COGS % of Revenue | 9.12% | 11.6% | 28.39% | 33.55% | 29.49% |
| Gross Profit | 21.41M | 27.68M | 27.24M | 31.06M | 39.9M |
| Gross Margin % | 90.88% | 88.4% | 71.61% | 66.45% | 70.51% |
| Gross Profit Growth % | - | 29.29% | -1.61% | 14.04% | 28.46% |
| Operating Expenses | 56.67M | 63.52M | 77.87M | 136.49M | 123.3M |
| OpEx % of Revenue | 240.53% | 202.83% | 204.74% | 292.01% | 217.88% |
| Selling, General & Admin | 42.97M | 50.58M | 64.89M | 119.64M | 119.02M |
| SG&A % of Revenue | 182.39% | 161.52% | 170.62% | 255.95% | 210.31% |
| Research & Development | 9.96M | 9.2M | 9.05M | 12.75M | 9.64M |
| R&D % of Revenue | 42.28% | 29.38% | 23.8% | 27.27% | 17.04% |
| Other Operating Expenses | 3.74M | 3.74M | 3.92M | 4.11M | -5.36M |
| Operating Income | -35.26M | -35.84M | -50.63M | -105.43M | -83.4M |
| Operating Margin % | -149.65% | -114.44% | -133.13% | -225.55% | -147.37% |
| Operating Income Growth % | - | -1.65% | -41.29% | -108.22% | 20.9% |
| EBITDA | -31.48M | -32.06M | -46.18M | -101.28M | -79.35M |
| EBITDA Margin % | -133.62% | -102.37% | -121.42% | -216.68% | -140.22% |
| EBITDA Growth % | - | -1.84% | -44.05% | -119.32% | 21.66% |
| D&A (Non-Cash Add-back) | 3.78M | 3.78M | 4.45M | 4.15M | 4.05M |
| EBIT | -35.26M | -76.66M | -13.76M | -113.25M | -70.84M |
| Net Interest Income | -13.12M | -11.76M | -9.6M | -1.07M | -1.96M |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 13.12M | 11.76M | 9.6M | 1.07M | 1.96M |
| Other Income/Expense | -12.31M | -52.58M | 27.27M | -8.89M | 10.59M |
| Pretax Income | -47.57M | -88.42M | -23.36M | -114.32M | -72.81M |
| Pretax Margin % | -201.92% | -282.34% | -61.42% | -244.57% | -128.66% |
| Income Tax | -53K | 5K | 4K | 13K | -1K |
| Effective Tax Rate % | 99.89% | 100.01% | 100.02% | 100.01% | 100% |
| Net Income | -47.52M | -88.42M | -23.36M | -114.33M | -72.81M |
| Net Margin % | -201.69% | -282.35% | -61.43% | -244.59% | -128.66% |
| Net Income Growth % | - | -86.08% | 73.58% | -389.35% | 36.32% |
| Net Income (Continuing) | -47.52M | -88.42M | -23.36M | -114.33M | -72.81M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.01 | -23.29 | -6.09 | -44.85 | -19.43 |
| EPS Growth % | - | -184741.27% | 73.85% | -636.45% | 56.68% |
| EPS (Basic) | -0.01 | -23.29 | -6.09 | -44.85 | -19.43 |
| Diluted Shares Outstanding | 4.03M | 3.8M | 3.83M | 3.72M | 6.95M |
| Basic Shares Outstanding | 4.03M | 3.8M | 3.83M | 3.72M | 6.95M |
| Dividend Payout Ratio | - | - | - | - | - |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Total Current Assets | 22.42M | 23M | 29.61M | 46.78M | 41.55M |
| Cash & Short-Term Investments | 4.84M | 4.34M | 2.18M | 3.92M | 3.27M |
| Cash Only | 4.84M | 4.34M | 2.18M | 3.92M | 3.27M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 13.13M | 14.27M | 21.24M | 34.6M | 26.44M |
| Days Sales Outstanding | 203.35 | 166.29 | 203.79 | 270.16 | 170.55 |
| Inventory | 1.15M | 2.56M | 1.38M | 4.21M | 2.44M |
| Days Inventory Outstanding | 194.47 | 257.33 | 46.58 | 98.09 | 53.28 |
| Other Current Assets | 0 | 1.83M | 0 | 0 | 9.4M |
| Total Non-Current Assets | 59.08M | 54.93M | 56.92M | 54.53M | 51.41M |
| Property, Plant & Equipment | 2.52M | 2.11M | 1.9M | 3.67M | 2.93M |
| Fixed Asset Turnover | 9.35x | 14.86x | 19.99x | 12.75x | 19.29x |
| Goodwill | 13.48M | 13.48M | 13.48M | 13.48M | 13.48M |
| Intangible Assets | 42.54M | 38.8M | 40.59M | 36.48M | 32.45M |
| Long-Term Investments | 0 | 0 | 0 | 808K | 2.42M |
| Other Non-Current Assets | 538K | 538K | 944K | 89K | 119K |
| Total Assets | 81.5M | 77.93M | 86.53M | 101.31M | 92.95M |
| Asset Turnover | 0.29x | 0.40x | 0.44x | 0.46x | 0.61x |
| Asset Growth % | - | -4.38% | 11.03% | 17.08% | -8.25% |
| Total Current Liabilities | 78.48M | 169.42M | 44.84M | 250.38M | 259.63M |
| Accounts Payable | 8.12M | 4.28M | 8.45M | 40.95M | 52.62M |
| Days Payables Outstanding | 1.38K | 430.29 | 285.66 | 953.27 | 1.15K |
| Short-Term Debt | 28.9M | 58.06M | 0 | 108.43M | 34.88M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 26.66M | 103.34M | 264K | 491K | 169.04M |
| Current Ratio | 0.29x | 0.14x | 0.66x | 0.19x | 0.16x |
| Quick Ratio | 0.27x | 0.12x | 0.63x | 0.17x | 0.15x |
| Cash Conversion Cycle | -981.33 | -6.66 | -35.28 | -585.03 | -927.01 |
| Total Non-Current Liabilities | 144.71M | 132.39M | 5.45M | 23.87M | 25.96M |
| Long-Term Debt | 107.66M | 95.54M | 0 | 17.04M | 845K |
| Capital Lease Obligations | 1.65M | 1.15M | 665K | 2.24M | 1.52M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 35.4M | 30.51M | 4.78M | 4.59M | 20.91M |
| Total Liabilities | 223.19M | 301.81M | 50.29M | 274.25M | 285.59M |
| Total Debt | 138.63M | 154.75M | 1.41M | 128.46M | 37.96M |
| Net Debt | 133.79M | 150.41M | -774K | 124.54M | 34.69M |
| Debt / Equity | - | - | 0.04x | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | -2.69x | -3.05x | -5.27x | -98.72x | -42.48x |
| Total Equity | -141.68M | -223.88M | 36.24M | -172.94M | -192.64M |
| Equity Growth % | - | -58.01% | 116.19% | -577.22% | -11.39% |
| Book Value per Share | -35.15 | -58.98 | 9.45 | -46.46 | -27.71 |
| Total Shareholders' Equity | -141.68M | -223.88M | 36.24M | -172.94M | -192.64M |
| Common Stock | 20K | 13K | 14K | 16K | 24K |
| Retained Earnings | -264.13M | -352.55M | -375.91M | -490.25M | -563.05M |
| Treasury Stock | 0 | 0 | 0 | -90.52M | -90.52M |
| Accumulated OCI | 0 | 0 | 0 | 0 | 6.32M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Cash from Operations | -31.46M | -28.66M | -21.26M | -20.71M | 19.35M |
| Operating CF Margin % | -133.54% | -91.53% | -55.89% | -44.3% | 34.19% |
| Operating CF Growth % | - | 8.89% | 25.84% | 2.59% | 193.44% |
| Net Income | -47.52M | -88.42M | -23.36M | -114.33M | -72.81M |
| Depreciation & Amortization | 3.78M | 3.78M | 3.96M | 4.15M | 4.05M |
| Stock-Based Compensation | 5.39M | 5.82M | 5.28M | 14.6M | 15.69M |
| Deferred Taxes | -800K | 12.76M | 0 | 0 | 0 |
| Other Non-Cash Items | 623K | 23.79M | -52.8M | 9.08M | 7.58M |
| Working Capital Changes | 7.06M | 13.6M | 45.67M | 65.8M | 64.84M |
| Change in Receivables | -598K | -1.14M | -6.97M | -13.36M | -6.27M |
| Change in Inventory | 2.38M | -1.42M | 1.18M | -2.84M | 1.46M |
| Change in Payables | -4.06M | -3.84M | 2.81M | 19.88M | 7.42M |
| Cash from Investing | -25K | 0 | -2.07M | -330K | -2.67M |
| Capital Expenditures | -25K | 0 | -2.07M | -30K | -600K |
| CapEx % of Revenue | 0.11% | - | 5.43% | 0.06% | 1.06% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -300K | 0 |
| Cash from Financing | -19.17M | 28.16M | 21.17M | 23.58M | -18.13M |
| Debt Issued (Net) | -37.62M | -19.69M | -31.25M | 728K | -64.21M |
| Equity Issued (Net) | -93.21K | 0 | 96K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -10M | 0 |
| Other Financing | 18.54M | 47.85M | 52.33M | -2.6M | 1.44M |
| Net Change in Cash | -50.66M | -501K | -2.15M | 2.54M | -1.46M |
| Free Cash Flow | -31.49M | -28.66M | -23.32M | -21.04M | 19.35M |
| FCF Margin % | -133.64% | -91.53% | -61.33% | -45.01% | 34.19% |
| FCF Growth % | - | 8.96% | 18.63% | 9.81% | 191.98% |
| FCF per Share | -7.81 | -7.55 | -6.08 | -5.65 | 2.78 |
| FCF Conversion (FCF/Net Income) | 0.66x | 0.32x | 0.91x | 0.18x | -0.27x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -64.47% | - | - |
| Return on Invested Capital (ROIC) | - | - | -107.08% | - | - |
| Gross Margin | 90.88% | 88.4% | 71.61% | 66.45% | 70.51% |
| Net Margin | -201.69% | -282.35% | -61.43% | -244.59% | -128.66% |
| Debt / Equity | - | - | 0.04x | - | - |
| Interest Coverage | -2.69x | -3.05x | -5.27x | -98.72x | -42.48x |
| FCF Conversion | 0.66x | 0.32x | 0.91x | 0.18x | -0.27x |
| Revenue Growth | - | 32.92% | 21.45% | 22.9% | 21.07% |
Explore detailed financial history, valuation models, and returns analysis
DCF models, peer multiples & analyst estimates
Historical returns with dividends reinvested
Yield, growth, payout safety & DRIP calculator
EPS trends, net income & profitability analysis
Long-term charts & historical price data
Sales growth patterns & revenue breakdown
30 years of valuation, profitability & efficiency metrics